Market Research Logo

Global Hemophilia Market Report: 2016 Edition

Global Hemophilia Market Report: 2016 Edition

Hemophilia refers to a set of hereditary genetic disorders that impairs the body's ability to control blood clotting, which controls bleeding when a blood vessel is broken. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. In the absence of a treatment, uncontrolled internal bleeding can occur, causing stiffness, pain, severe joint damage and even death. Depending upon the coagulation factor deficiency, there are different types of hemophilia such as Hemophilia A, Hemophilia B, Hemophilia C, Von Willebrand disease and Hemophilia with Inhibitors.

Even though Hemophilia is rare bleeding disorder, the number of people affected by it has been increasing with time. While mild hemophilia is easy to diagnose especially in kids, when they learn to move and walk, and get large bruises from minute falls, severe hemophilia patients need to go for periodic transfusion of the respective factors so as to avoid the event of life-threatening bleeding episodes. Such a periodic transfusion is done through what is commonly known as the replacement therapy. With increasing sophistication and modernization of technology, demand for advanced treatment options increases, thereby making the entire market grow.

The key factors which are anticipated to drive this market include increasing penetration of recombinant factor VIII, increasing healthcare expenditure, emerging use of treatments in low income countries and increasing diagnosis rates. Some of the noteworthy progresses of this industry include the increasing adoption of prophylaxis therapy, introduction of extended half-life products and gene therapy. However, the growth of respective industry is challenged by the high cost of treatments and high reluctance by patients to switch to new treatments/products.

The report provides a comprehensive study of global hemophilia market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global hemophilia industry is highly competitive consisting of several large companies including the Shire Plc, Bayer Group, Pfizer Inc, Novo Nordisk etc. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail."


1. Overview
1.1 Types of Hemophilia
Table 1: Types of Hemophilia
1.1.1 Hemophilia A
1.1.2 Hemophilia B
1.1.3 Hemophilia C
1.1.4 Hemophilia with Inhibitors
1.1.5 Von Willebrands Disease
1.2 Signs and Symptoms
1.3 Treatments of Hemophilia
1.3.1 Replacement Therapy
2. Market Analysis
2.1 Global Hemophilia Market
2.1.1 Global Hemophilia Prevalence
Table 2: Global Hemophilia Prevalence (2015)
2.1.2 Global Hemophilia Diagnosis and Treatment
Table 3: Global Hemophilia Diagnosis and Treatment Ratio (2015)
2.1.3 Global Hemophilia Market Revenue
Table 4: Global Hemophilia Market Revenue (2015E-2020F)
Table 5: Global Hemophilia Revenue Share by Category (2015E)
Table 6: Global Hemophilia Revenue Share by Category –Forecast (2020)
2.1.4 Global Demand for FVIII for Hemophilia A
Table 7: Global FVIII Demand by Volume (2011-2015E)
Table 8: Global FVIII Demand by Category - Volume (2015E-2017E)
2.1.5 Global Supply Capacity of Recombinant FVIII for Hemophilia A
Table 9: Global Supply Capacity of Recombinant FVIII – Actual (2011-2015E)
Table 10: Global Supply Capacity of Recombinant FVIII – Forecast (2016F-2017F)
2.1.6 Global Hemophilia A Market Revenue
Table 11: Global Hemophilia A Market Revenue (2015E-2020F)
Table 12: Global Hemophilia A Revenue Share by Category (2015E)
2.1.7 Global Hemophilia B Market Revenue
Table 13: Global Hemophilia B Market Revenue (2015E-2020F)
2.1.8 Global Hemophilia with Inhibitors Market Revenue
Table 14: Global Hemophilia with Inhibitors Market Revenue (2015E-2020F)
2.2 The US Hemophilia Market
2.2.1The US Hemophilia Patients Treated per Year
Table 15: The US Hemophilia Patients Treated per Year (2013-2020F)
2.2.2 The US Hemophilia Market Revenue
Table 16: The US Hemophilia Market Revenue (2013-2015E)
Table 17: The US Hemophilia Market Revenue – Forecast (2016F-2020F)
2.2.3 The US Hemophilia A Patients Treated per Year
Table 18: The US Hemophilia A Patients Treated per Year (2013-2020F)
2.2.4 The US Hemophilia A Market Revenue
Table 19: The US Hemophilia A Market Revenue (2013-2020F)
2.2.5 The US Hemophilia B Patients Treated per Year
Table 20: The US Hemophilia B Patients Treated per Year (2013-2020F)
2.2.6 The US Hemophilia B Market Revenue
Table 21: The US Hemophilia B Market Revenue (2013-2020F)
2.2.7 The US Hemophilia with Inhibitors Patients Treated per Year
Table 22: The US Hemophilia with Inhibitors Patients Treated per Year (2013-2020F)
2.2.8 The US Hemophilia with Inhibitors Market Revenue
Table 23: The US Hemophilia with Inhibitors Market Revenue (2013-2020F)
2.2.9 The US Von Willebrand Factor Market Revenue
Table 24: The US Von Willebrand Factor Market Revenue (2013-2020F)
2.3 Europe Hemophilia Market
2.3.1 Europe Hemophilia Patients
Table 25: Europe Hemophilia Patients (2014-2020F)
2.3.2 Europe Hemophilia A Patients
Table 26: Europe Hemophilia A Patients (2014-2020F)
Table 27: Europe Hemophilia A Patients by Severity (2015E)
2.3.3 Europe Hemophilia A Therapy by Severity
Table 28: Europe Hemophilia A Therapy by Severity (2015E)
2.3.4 Europe Hemophilia B Patients
Table 29: Europe Hemophilia B Patients (2015E-2020F)
Table 30: Europe Hemophilia B Patients by Severity (2015E)
2.3.5 Europe Hemophilia B Therapy by Severity
Table 31: Europe Hemophilia B Therapy by Severity (2015E)
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Increasing Penetration of Recombinant FVIII
Table 32: Penetration of Recombinant FVIII (2014)
3.1.2 Increasing Healthcare Expenditures
Table 33: Global Healthcare Expenditure Per Capita (2009-2014E)
3.1.3 Emerging Use of Treatments in Low Income Countries
Table 34: Global Per Capita Usage of FVIII by Income Groups (2014)
3.1.4 Increasing Diagnosis Rate
3.2 Key Trends
3.2.1 Increasing adoption of Prophylaxis
Table 35: Prophylaxis Therapy Usage by Category (2015E)
3.2.2 Gene Therapy
Table A: Gene Therapy Products under Development (2015)
3.2.3 Introduction of Extended Half-Life Products
Table B: Extended Half-Life Products under Development (2015)
3.3 Challenges
3.3.1 High Cost of Treatment
3.3.2 Reluctance to Switch to New Treatments/Products
4. Competitive Landscape
4.1 Competition by Market Share
4.1.1 Hemophilia Market Share
Table 36: Global Hemophilia Market Share (2015E)
4.1.2 Hemophilia A Market Share
Table 37: Global Hemophilia A Market Share (2015E)
4.2 Competition by Financials
4.2.1 Competition by Market Cap
Table 38: Market Capitalization Comparison (2015)
4.2.2 Competition by Profit Margin
Table 39: Gross Profit Margin Comparison (2015)
5. Company Profiles
5.1 Shire PLC
5.1.1 Business Overview
Table 40: Revenue Share by Product Category, Shire PLC (2015)
5.1.2 Financial Overview
Table 41: Revenue and Net Income, Shire PLC (2011-2015)
5.1.3 Business Strategies
5.2 Bayer Group
5.2.1 Business Overview
Table 42: Revenue Share by Business Segments, Bayer Group (2015)
5.2.2 Financial Overview
Table 43: Revenue and Net Income, BAYER (2011-2015)
5.2.3 Business Strategies
5.3 Novo Nordisk
5.3.1 Business Overview
Table 44: Revenue Share by Business Segments, Novo Nordisk (2015)
5.3.2 Financial Overview
Table 45: Revenue and Net Income, Novo Nordisk (2011-2015)
5.3.3 Business Strategies
5.4 Pfizer Inc.
5.4.1 Business Overview
Table 46: Revenue Share by Business Segments, Pfizer Inc. (2015)
5.4.2 Financial Overview
Table 47: Revenue and Net Income, Pfizer (2011-2015)
5.4.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report